Biogen (BIIB) PT Raised to $260 at RBC Capital, 'Deep Dive Suggests Upcoming Liti SLE Data Could Start I&I Buildout On Right Path'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams raised the price target on Biogen (NASDAQ: BIIB) to $260.00 (from $240.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
